A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacodynamic Response, and Pharmacokinetics of Intravenous Infusions of BAN2401 in Subjects With Mild to Moderate Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2013
At a glance
- Drugs BAN 2401 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 17 Jul 2013 Results presented at the 2013 Alzheimer's Association International Conference .
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Dec 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.